US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Valeritas Holdings, Inc.

0.2568

0.0000

Volume:- -

Turnover:- -

Market Cap:2.14M

PE:-0.02

High:0.2568

Open:0.2568

Low:0.2568

Close:0.2568

52wk High:11.39

52wk Low:0.2500

Shares:8.33M

Float Shares:6.44M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-10.7196

EPS(LYR):-34.2167

ROE:-2955.84%

ROA:-66.46%

PB:0.19

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?

Simply Wall St.

Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential

Simply Wall St.

Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/VLRX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VLRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VLRX\",,,,,undefined,":{"symbol":"VLRX","market":"US","secType":"STK","nameCN":"Valeritas Holdings, Inc.","latestPrice":0.2568,"timestamp":1582146000000,"preClose":0.2568,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":6440176,"shares":8331503,"eps":-10.719572,"marketStatus":"Delisted","change":0,"latestTime":"02-19 16:00:00 EST","open":0.2568,"high":0.2568,"low":0.2568,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-10.719572,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1490241600000,"exchange":"NASDAQ","adjPreClose":0.2568,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VLRX\",,,,,undefined,":{"symbol":"VLRX","floatShares":6440176,"roa":"-66.46%","roe":"-2955.84%","lyrEps":-34.216745,"shares":8331503,"dividePrice":0,"high":0.2568,"amplitude":0,"preClose":0.2568,"low":0.2568,"week52Low":0.25,"pbRate":"0.19","week52High":11.394,"institutionHeld":0,"latestPrice":0.2568,"eps":-10.719572,"divideRate":0,"volume":0,"delay":0,"ttmEps":-10.719572,"open":0.2568},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VLRX\",params:#limit:5,,,undefined,":[{"date":"2019-11-12","symbol":"VLRX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-2.38,"defaultRemindTime":1573592400000,"name":null,"time":"Post Market","dateTimestamp":1573534800000,"actualEps":null},{"date":"2019-08-08","symbol":"VLRX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-2.9,"defaultRemindTime":1565294400000,"name":null,"time":"Post Market","dateTimestamp":1565236800000,"actualEps":-12.4},{"market":"US","date":"2019-05-20","symbol":"VLRX","type":"split","dateTimestamp":1558324800000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2019-05-09","symbol":"VLRX","fiscalQuarterEnding":"2019/03","expectedEps":-0.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1557374400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2019-03-05","symbol":"VLRX","fiscalQuarterEnding":"2018/12","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1551762000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VLRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VLRX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VLRX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2604744915","title":"Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604744915","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604744915?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:30","pubTimestamp":1768584634,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals has recently begun dosing in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform, marking the first formal evaluation of this next-generation delivery technology.\nThis step signals an effort to build a broader pipeline based on in-house intellectual property that could diversify the business beyond its existing treatment franchise if development progresses successfully.\nWe’ll now explore how advancing the proprietary VLRX-L...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","VLRX","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2603545606","title":"Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2603545606","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603545606?lang=en_us&edition=fundamental","pubTime":"2026-01-15 15:34","pubTimestamp":1768462462,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nThe VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","VLRX","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2602563594","title":"Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563594","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563594?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:37","pubTimestamp":1768171045,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals has begun dosing in a new preclinical study of VLRX-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clinuvel-starts-preclinical-dosing-of-new-controlled-release-peptide-platform-vlrx-l?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clinuvel-starts-preclinical-dosing-of-new-controlled-release-peptide-platform-vlrx-l?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VLRX"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VLRX\",params:#limit:6,delay:false,,,undefined,":[]}}